Defining the Risk of Ventricular Tachycardia in Genetic Forms of Early-onset Atrial Fibrillation

Stopped early

Conditions studied: Ventricular Tachycardia, Atrial Fibrillation

In brief

To use programmed ventricular stimulation at the time of AF ablation to define the prevalence and mechanism of inducible ventricular tachycardia (VT); pace-mapping to define the site of origin of ventricular arrhythmias; and voltage mapping to define low voltage scar substrate in the basal LV in patients with pathogenic TTN variants compared to genotype-negative controls.

Key facts

Study ID

NCT06647459

Run by

Vanderbilt University Medical Center

People needed

32

Starts

2023-12-13

Expected to finish

2026-04-28

Last updated by the study team

2026-05-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Adults aged 18 and older
• Diagnosed with AF before age 60
• Scheduled for catheter-based AF ablation (de-novo or repeat)
• Able to provide written, informed consent
• P/LP variant in TTN or other CM gene (cases) or identified as a genotype-negative control.

You may not qualify if…

• Diagnosed with a genetic CM or arrhythmia syndrome prior to AF
• VUS in 'possibly pathogenic' subgroup (control group only)
• Pacemaker or ICD
• Previous PVC or VT ablation
• LVEF <20%
• Prosthetic mitral or aortic valve
• Contraindication to heparin
• Prior myocardial infarction.

Where it is running

• Vanderbilt University Medical Center — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.